Mereo BioPharma Group Stock (NASDAQ:MREO)
Previous Close
$4.09
52W Range
$1.86 - $5.02
50D Avg
$4.30
200D Avg
$3.75
Market Cap
$655.41M
Avg Vol (3M)
$757.04K
Beta
0.97
Div Yield
-
MREO Company Profile
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
MREO Performance
Peer Comparison
Ticker | Company |
---|---|
XFOR | X4 Pharmaceuticals, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
PDSB | PDS Biotechnology Corporation |
HOOK | HOOKIPA Pharma Inc. |
TERN | Terns Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
EFTR | eFFECTOR Therapeutics, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
ELEV | Elevation Oncology, Inc. |
AMLX | Amylyx Pharmaceuticals, Inc. |